CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade 2seventy bio, Inc. - TSVT CFD

    3.06
    16.35%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 2.63
    Open* 2.66
    1-Year Change* -81.49%
    Day's Range* 2.66 - 3.06
    52 wk Range 1.55-16.17
    Average Volume (10 days) 1.93M
    Average Volume (3 months) 37.79M
    Market Cap 79.48M
    P/E Ratio -100.00K
    Shares Outstanding 50.62M
    Revenue 145.88M
    EPS -3.91
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date Mar 11, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 8, 2023 3.06 0.44 16.79% 2.62 3.08 2.56
    Dec 7, 2023 2.63 0.31 13.36% 2.32 2.67 2.26
    Dec 6, 2023 2.32 0.23 11.00% 2.09 2.44 2.09
    Dec 5, 2023 2.13 0.10 4.93% 2.03 2.18 2.00
    Dec 4, 2023 2.04 0.16 8.51% 1.88 2.18 1.86
    Dec 1, 2023 1.92 0.12 6.67% 1.80 1.92 1.65
    Nov 30, 2023 1.81 -0.08 -4.23% 1.89 1.95 1.80
    Nov 29, 2023 1.89 0.04 2.16% 1.85 2.06 1.85
    Nov 28, 2023 1.84 0.01 0.55% 1.83 1.89 1.72
    Nov 27, 2023 1.79 0.04 2.29% 1.75 1.87 1.70
    Nov 24, 2023 1.71 0.04 2.40% 1.67 1.87 1.64
    Nov 22, 2023 1.71 0.13 8.23% 1.58 1.71 1.51
    Nov 21, 2023 1.54 -0.17 -9.94% 1.71 1.72 1.53
    Nov 20, 2023 1.71 0.03 1.79% 1.68 1.84 1.63
    Nov 17, 2023 2.10 -0.08 -3.67% 2.18 2.27 2.02
    Nov 16, 2023 2.09 -0.21 -9.13% 2.30 2.30 2.05
    Nov 15, 2023 2.29 0.08 3.62% 2.21 2.48 2.21
    Nov 14, 2023 2.24 0.13 6.16% 2.11 2.61 1.86
    Nov 13, 2023 2.23 0.13 6.19% 2.10 2.24 1.99
    Nov 10, 2023 2.14 -0.14 -6.14% 2.28 2.28 2.14

    2seventy bio, Inc. Events

    Time (UTC) Country Event
    Monday, March 11, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 2Seventy Bio Inc Earnings Release
    Q4 2023 2Seventy Bio Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 91.496 54.522 248.122 44.296 54.579
    Revenue 91.496 54.522 248.122 44.296 54.579
    Cost of Revenue, Total 16.577 2.517 5.396 2.978 0.885
    Gross Profit 74.919 52.005 242.726 41.318 53.694
    Total Operating Expense 354.636 368.47 386.292 385.016 258.005
    Selling/General/Admin. Expenses, Total 79.45 93.506 90.897 81.646 53.631
    Research & Development 248.735 261.937 296.467 297.645 200.49
    Other Operating Expenses, Total 0.232 0.439 -6.468 2.747 2.999
    Operating Income -263.14 -313.948 -138.17 -340.72 -203.426
    Interest Income (Expense), Net Non-Operating 2.932 0.088 0 0 -15.486
    Other, Net 6.055 21.647 18.056 20.126 19.163
    Net Income Before Taxes -254.153 -292.213 -120.114 -320.594 -199.749
    Net Income After Taxes -254.153 -292.213 -120.114 -320.594 -199.749
    Net Income Before Extra. Items -254.153 -292.213 -120.114 -320.594 -199.749
    Net Income -254.153 -292.213 -120.114 -320.594 -199.749
    Income Available to Common Excl. Extra. Items -254.153 -292.213 -120.114 -320.594 -199.749
    Income Available to Common Incl. Extra. Items -254.153 -292.213 -120.114 -320.594 -199.749
    Diluted Net Income -254.153 -292.213 -120.114 -320.594 -199.749
    Diluted Weighted Average Shares 35.637 23.499 23.3691 23.3691 23.3691
    Diluted EPS Excluding Extraordinary Items -7.13172 -12.4351 -5.13987 -13.7187 -8.54757
    Dividends per Share - Common Stock Primary Issue 0 0 0
    Diluted Normalized EPS -6.86116 -12.0065 -5.13987 -13.7187 -8.54757
    Unusual Expense (Income) 9.642 10.071
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 36.048 41.621 56.177 13.408 13.482
    Revenue 36.048 41.621 56.177 13.408 13.482
    Cost of Revenue, Total 4.517 4.295 15.325 0.377 4.246
    Gross Profit 31.531 37.326 40.852 13.031 9.236
    Total Operating Expense 84.039 93.334 83.389 81.776 90.454
    Selling/General/Admin. Expenses, Total 19.489 20.72 18.701 19.61 17.278
    Research & Development 59.98 68.246 49.312 61.739 64.557
    Other Operating Expenses, Total 0.053 0.073 0.051 0.05 0.083
    Operating Income -47.991 -51.713 -27.212 -68.368 -76.972
    Interest Income (Expense), Net Non-Operating 3.09 2.049 1.491 1.113 0.213
    Other, Net 2.812 2.643 2.561 -0.624 -0.661
    Net Income Before Taxes -42.089 -47.021 -23.16 -67.879 -77.42
    Net Income After Taxes -42.089 -47.021 -23.143 -67.879 -77.42
    Net Income Before Extra. Items -42.089 -47.021 -23.143 -67.879 -77.42
    Net Income -42.089 -47.021 -23.143 -67.879 -77.42
    Income Available to Common Excl. Extra. Items -42.089 -47.021 -23.143 -67.879 -77.42
    Income Available to Common Incl. Extra. Items -42.089 -47.021 -23.143 -67.879 -77.42
    Diluted Net Income -42.089 -47.021 -23.143 -67.879 -77.42
    Diluted Weighted Average Shares 50.966 43.468 38.712 38.573 38.381
    Diluted EPS Excluding Extraordinary Items -0.82583 -1.08174 -0.59782 -1.75975 -2.01714
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.82583 -1.08174 -0.59782 -1.75975 -1.90537
    Unusual Expense (Income) 0 0 0 0 4.29
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 300.882 291.564 25.104 20.842
    Total Receivables, Net 20.96 16.995 10.691 7.426
    Accounts Receivable - Trade, Net 20.96 16.995 10.691 7.426
    Prepaid Expenses 13.652 9.512 14.413 13.416
    Total Assets 656.665 759.675 312.62 314.949
    Property/Plant/Equipment, Total - Net 296.62 310.447 260.481 257.521
    Property/Plant/Equipment, Total - Gross 344.458 350.525 290.518 278.237
    Accumulated Depreciation, Total -47.838 -40.078 -30.037 -20.716
    Goodwill, Net 12.056 12.056 13.128 13.128
    Intangibles, Net 7.302 9.892 5.644 9.406
    Other Long Term Assets, Total 38.391 38.592 8.263 14.052
    Total Current Liabilities 79.794 98.388 75.868 103.397
    Accounts Payable 7.208 6.024 7.152 20.389
    Accrued Expenses 65.842 65.179 58.66 64.154
    Notes Payable/Short Term Debt 0 0 0 0
    Other Current Liabilities, Total 6.744 27.185 10.056 18.854
    Total Liabilities 346.199 399.853 237.991 271.257
    Total Long Term Debt 0 0 0 0
    Other Liabilities, Total 266.405 301.465 162.123 167.86
    Total Equity 310.466 359.822 74.629 43.692
    Other Equity, Total -2.877 -0.712 74.629 43.692
    Total Liabilities & Shareholders’ Equity 656.665 759.675 312.62 314.949
    Total Common Shares Outstanding 37.928 23.585 23.3691 23.3691
    Cash and Short Term Investments 266.27 265.057
    Cash & Equivalents 71.032 130.414
    Short Term Investments 195.238 134.643
    Long Term Investments 1.414 97.124
    Common Stock 0.004 0.002
    Additional Paid-In Capital 606.986 400.026
    Retained Earnings (Accumulated Deficit) -293.647 -39.494
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 277.254 333.665 389.817 300.882 349.417
    Total Receivables, Net 19.515 44.099 41.252 20.96 12.037
    Accounts Receivable - Trade, Net 19.515 44.099 41.252 20.96 12.037
    Prepaid Expenses 7.12 6.729 8.635 13.652 14.27
    Total Assets 640.806 705.713 742.437 656.665 708.744
    Property/Plant/Equipment, Total - Net 285.234 291.735 294.417 296.62 300.108
    Property/Plant/Equipment, Total - Gross 339.292 343.712 344.332 344.458 345.798
    Accumulated Depreciation, Total -54.058 -51.977 -49.915 -47.838 -45.69
    Goodwill, Net 0 12.056 12.056 12.056 12.056
    Intangibles, Net 6.771 6.948 7.125 7.302 7.479
    Other Long Term Assets, Total 37.888 37.6 37.59 38.391 38.277
    Total Current Liabilities 68.008 66.895 76.929 79.794 79.897
    Accounts Payable 5.307 6.274 13.399 7.208 7.983
    Accrued Expenses 49.675 47.979 55.05 65.842 62.954
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 13.026 12.642 8.48 6.744 8.96
    Total Liabilities 334.384 338.218 341.113 346.199 385.564
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 266.376 271.323 264.184 266.405 305.667
    Total Equity 306.422 367.495 401.324 310.466 323.18
    Other Equity, Total -0.916 -1.43 -1.95 -2.877 -3.886
    Total Liabilities & Shareholders’ Equity 640.806 705.713 742.437 656.665 708.744
    Total Common Shares Outstanding 50.616 50.238 50.19 37.928 37.912
    Cash and Short Term Investments 250.619 282.837 339.93 266.27 323.11
    Cash & Equivalents 90.226 95.991 193.629 71.032 127.021
    Short Term Investments 160.393 186.846 146.301 195.238 196.089
    Long Term Investments 33.659 23.709 1.432 1.414 1.407
    Common Stock 0.005 0.005 0.005 0.004 0.004
    Additional Paid-In Capital 761.728 751.677 743.937 606.986 597.566
    Retained Earnings (Accumulated Deficit) -454.395 -382.757 -340.668 -293.647 -270.504
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -254.153 -292.213 -120.114 -320.594 -199.749
    Cash From Operating Activities -237.134 -207.034 -67.793 -207.957 -146.215
    Cash From Operating Activities 11.533 16.35 13.188 12.587 13.345
    Non-Cash Items 41.357 55.498 54.602 64.906 44.007
    Cash Taxes Paid 0 0 0 0 0
    Cash Interest Paid 0 0 0 0 15.486
    Changes in Working Capital -35.871 13.331 -15.469 35.144 -3.818
    Cash From Investing Activities 11.697 15.411 -22.261 -59.765 -50.827
    Capital Expenditures -22.842 -19.575 -22.261 -59.765 -50.827
    Cash From Financing Activities 166.229 354.889 90.054 267.722 197.042
    Financing Cash Flow Items 0 0 3.098
    Issuance (Retirement) of Stock, Net 166.229 354.889 90.054 267.722 194.961
    Issuance (Retirement) of Debt, Net 0 0 -1.017
    Net Change in Cash -59.208 163.266 0 0 0
    Other Investing Cash Flow Items, Total 34.539 34.986
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -47.021 -254.153 -231.01 -163.131 -85.711
    Cash From Operating Activities -49.088 -237.134 -181.654 -120.725 -73.482
    Cash From Operating Activities 2.255 11.533 9.208 6.831 3.53
    Non-Cash Items 8.535 41.357 32.89 20.866 11.014
    Cash Taxes Paid 0
    Cash Interest Paid 0
    Changes in Working Capital -12.857 -35.871 7.258 14.709 -2.315
    Cash From Investing Activities 44.798 11.697 12.229 94.519 44.749
    Capital Expenditures -6.079 -22.842 -19.676 -6.258 -3.585
    Cash From Financing Activities 127.084 166.229 165.997 165.822 170.099
    Financing Cash Flow Items
    Issuance (Retirement) of Stock, Net 127.084 166.229 165.997 165.822 170.099
    Issuance (Retirement) of Debt, Net
    Net Change in Cash 122.794 -59.208 -3.428 139.616 141.366
    Other Investing Cash Flow Items, Total 50.877 34.539 31.905 100.777 48.334
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Kynam Capital Management LP Hedge Fund 11.798 5953825 1063119 2023-08-31 MED
    BlackRock Institutional Trust Company, N.A. Investment Advisor 7.187 3626865 842492 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 6.8785 3471194 573640 2023-06-30 LOW
    Millennium Management LLC Hedge Fund 5.7376 2895476 383825 2023-06-30 HIGH
    Wellington Management Company, LLP Investment Advisor/Hedge Fund 5.7068 2879922 110480 2023-06-30 LOW
    Baker Bros. Advisors LP Hedge Fund 4.9491 2497526 0 2023-06-30 LOW
    OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 4.7392 2391628 0 2023-06-30 LOW
    Casdin Capital, LLC Hedge Fund 4.0106 2023913 0 2023-06-30 LOW
    ExodusPoint Capital Management, LP Hedge Fund 2.8879 1457390 428350 2023-06-30 HIGH
    Bain Capital Life Sciences Investors, LLC Investment Advisor 2.7919 1408901 0 2023-06-30 LOW
    Avidity Partners Management LP Hedge Fund 2.6593 1342000 1342000 2023-06-30 HIGH
    Goldman Sachs & Company, Inc. Research Firm 2.5416 1282617 -154546 2023-06-30 MED
    Point72 Asset Management, L.P. Hedge Fund 2.5304 1276952 1065673 2023-06-30 HIGH
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.1186 1069125 -1991081 2023-09-30 LOW
    Credit Suisse Funds AG Investment Advisor/Hedge Fund 2.0023 1010450 -7315 2023-06-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.9483 983226 241754 2023-06-30 LOW
    Cowen Investment Management LLC Investment Advisor/Hedge Fund 1.6883 852007 -2993 2023-06-30 HIGH
    JP Morgan Asset Management Investment Advisor 1.4683 740947 -367190 2023-06-30 LOW
    Newtyn Management, LLC Hedge Fund 1.4619 737744 -767256 2023-06-30 MED
    Morgan Stanley & Co. LLC Research Firm 1.3142 663190 -216995 2023-06-30 MED

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    2seventy bio, Inc. Company profile

    About 2Seventy Bio Inc

    2Seventy Bio, Inc. is a cell and gene therapy company. The Company is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. It is advancing multiple preclinical and clinical programs in oncology. The Company's lead preclinical programs in B cell non-Hodgkin's lymphoma (B-NHL) and acute myeloid leukemia are illustrations of its multiplex approach applied to address the specific challenges of treating those cancers. It is developing bbT369 product candidate as a treatment for patients with B-NHL.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, 2Seventy Bio Inc revenues totaled $38.5M. Net loss totaled to $231.2M.

    Industry: Biotechnology & Medical Research (NEC)

    60 Binney Street
    CAMBRIDGE
    MASSACHUSETTS 02210
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    BTC/USD

    44,047.25 Price
    -1.270% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Gold

    2,004.85 Price
    -1.180% 1D Chg, %
    Long position overnight fee -0.0198%
    Short position overnight fee 0.0116%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    Oil - Crude

    71.41 Price
    +2.320% 1D Chg, %
    Long position overnight fee -0.0204%
    Short position overnight fee -0.0015%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    XRP/USD

    0.68 Price
    +0.260% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading